Clinical Trials Using Rituximab and Hyaluronidase Human
Clinical trials are research studies that involve people. The clinical trials on this list are studying Rituximab and Hyaluronidase Human. All trials on the list are supported by NCI.
NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
This randomized phase III trial studies rituximab after stem cell transplant and to see how well it works compared with rituximab alone in treating patients with in minimal residual disease-negative mantle cell lymphoma in first complete remission. Immunotherapy with rituximab, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread. Giving chemotherapy before a stem cell transplant helps kill any cancer cells that are in the body and helps make room in the patient’s bone marrow for new blood-forming cells (stem cells) to grow. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy is then given to prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the patient to replace the blood-forming cells that were destroyed by the chemotherapy. Giving rituximab with or without stem cell transplant may work better in treating patients with mantle cell lymphoma.
Location: 320 locations
Ibrutinib and Rituximab for the Treatment of Treatment Naive Marginal Zone Lymphoma
This phase III trial studies how well ibrutinib and rituximab work compared with rituximab alone in treating patients with marginal zone lymphoma who have not received prior treatment for the disease (treatment naive). Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and rituximab may work better in treating patients with marginal zone lymphoma compared to rituximab alone.
Location: 12 locations
Umbralisib and Rituximab as Initial Therapy for Follicular Lymphoma and Marginal Zone Lymphoma
This phase II trial studies how well umbralisib and rituximab work as initial therapy for patients with follicular lymphoma and marginal zone lymphoma. Umbralisib blocks a protein called P13K, that plays a role in the way cells grow. In follicular lymphoma and marginal zone lymphoma, P13K is increased and more active than usual, allowing cancer cells to grow and survive. Umbralisib may kill cancer cells in some patients and cause their tumors to shrink. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Umbralisib and rituximab combination may work better than standard initial therapies in patients with follicular lymphoma and marginal zone lymphoma.
Location: 2 locations
Venetoclax, Rituximab, and Rituximab and Hyaluronidase Human in Treating Participants with Recurrent or Refractory Chronic Lymphocytic Leukemia
This phase II trial studies the side effects and how well venetoclax, rituximab, and rituximab and hyaluronidase human work in treating participants with chronic lymphocytic leukemia that has come back (recurrent) or that does not respond to treatment (refractory). Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as rituximab and rituximab and hyaluronidase human, may interfere with the ability of cancer cells to grow and spread or may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax, rituximab, and rituximab and hyaluronidase human may work better in treating participants with recurrent or refractory chronic lymphocytic leukemia.
Location: 2 locations
Rituximab Hyaluronidase in Combination with Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
This phase I trial studies how well rituximab hyaluronidase and combination chemotherapy work in treating patients in Uganda with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric Castleman disease. Rituximab hyaluronidase is a combination of rituximab and hyaluronidase. Rituximab binds to a molecule called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Hyaluronidase allows rituximab to be given by injection under the skin. Giving rituximab and hyaluronidase by injection under the skin is faster than giving rituximab alone by infusion into the blood. Drugs used in chemotherapy, such as cyclophosphamide, vincristine, methotrexate, etoposide, doxorubicin, and prednisone work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. While rituximab has a clear survival benefit in patients within developed countries, differences in supportive care and infectious co-morbidities require special attention. Giving rituximab hyaluronidase alone or in combination with chemotherapy may work better in treating patients with Burkitt lymphoma, diffuse large B-cell lymphoma, or Kaposi sarcoma herpesvirus associated multicentric Castleman disease compared to chemotherapy alone in Uganda.
Location: Fred Hutch / University of Washington Cancer Consortium, Seattle, Washington
Rituximab and Hyaluronidase Human in Treating Patients with Unresectable Stage III-IV Melanoma Undergoing Nivolumab and Ipilimumab Therapy
This phase II trial studies how well rituximab and hyaluronidase human works in treating patients with stage III-IV melanoma that cannot be removed by surgery who are undergoing nivolumab and ipilimumab therapy. Immunotherapy with rituximab and hyaluronidase human, may induce changes in body’s immune system and may interfere with the ability of tumor cells to grow and spread.
Location: Emory University Hospital / Winship Cancer Institute, Atlanta, Georgia